Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Indivior Pharmaceuticals, Inc.

Capitalization 3.89B 3.4B 3.07B 2.94B 5.35B 360B 5.56B 36.71B 14.55B 172B 14.6B 14.29B 621B P/E ratio 2026 *
11.5x
P/E ratio 2027 * 9.78x
Enterprise value 3.67B 3.21B 2.9B 2.78B 5.05B 340B 5.25B 34.67B 13.74B 162B 13.79B 13.5B 587B EV / Sales 2026 *
3.17x
EV / Sales 2027 * 2.85x
Free-Float
96.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.81%
1 week-3.59%
Current month-4.92%
1 month-10.03%
3 months-12.51%
6 months+34.04%
Current year-13.29%
1 week 29.4
Extreme 29.4
35.34
1 month 29.4
Extreme 29.4
35.57
Current year 29.4
Extreme 29.4
37.66
1 year 8.64
Extreme 8.64
38
3 years 7.33
Extreme 7.33
38
5 years 7.33
Extreme 7.33
38
10 years 1.75
Extreme 1.75
38
Change 5d. change 1-year change 3-years change Capi.($)
+0.81%-3.59%+224.40%+75.27% 3.89B
+0.80%-0.53%+22.88%+203.58% 880B
-0.21%+0.47%+48.18%+57.79% 582B
-2.52%-4.53%+3.84%+44.57% 388B
+0.79%-6.01%+5.81%+21.36% 324B
+0.11%-0.83%+21.02%+34.57% 295B
+0.43%-1.54%+25.20%+62.42% 293B
-0.26%-0.16%+22.07%+9.34% 286B
-0.43%-0.90%+17.13%+57.05% 197B
+0.42%+0.74%+27.91%+82.35% 180B
Average -0.18%-1.69%+41.85%+64.83% 343.01B
Weighted average by Cap. -0.38%-1.37%+23.53%+85.88%

Financials

2026 *2027 *
Net sales 1.16B 1.01B 916M 876M 1.59B 107B 1.66B 10.94B 4.34B 51.24B 4.35B 4.26B 185B 1.22B 1.07B 964M 922M 1.68B 113B 1.74B 11.52B 4.56B 53.95B 4.58B 4.48B 195B
Net income 353M 309M 279M 267M 486M 32.69B 505M 3.33B 1.32B 15.62B 1.33B 1.3B 56.4B 413M 361M 326M 312M 567M 38.16B 589M 3.89B 1.54B 18.23B 1.55B 1.52B 65.85B
Net Debt -216M -189M -170M -163M -297M -19.97B -308M -2.04B -807M -9.54B -810M -793M -34.46B -412M -361M -326M -312M -567M -38.15B -589M -3.89B -1.54B -18.23B -1.55B -1.52B -65.83B
Logo Indivior Pharmaceuticals, Inc.
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
Employees
833
Date Price Change Volume
26-03-13 31.11 $ +0.81% 13,297,326
26-03-12 30.86 $ -6.00% 6,980,936
26-03-11 32.83 $ -1.53% 3,578,787
26-03-10 33.34 $ +2.27% 4,399,505
26-03-09 32.60 $ +1.02% 2,782,795
Trader
Investor
Global
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
31.11USD
Average target price
46.86USD
Spread / Average Target
+50.62%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW